NCT07402109Recruiting
CBCT Guided Markerless SBRT for Renal Cell Cancer
Organ Sparing Marker-less CBCT-guided Stereotactic Adaptive Radiotherapy for Primary Non-metastasized Renal Tumors
Source: ClinicalTrials.gov · Last updated 8 Apr 2026
Brief summary (registry, in English)
This study aims to improve the treatment of kidney tumors using radiotherapy, by investigating whether kidney cancer can be more effectively irradiated with the help of new imaging techniques
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 30 Sept 2025
- Start date
- Apr 2026
- Primary completion date
- Jan 2030
- Lead sponsor
- Erasmus Medical Center
- Diseases
- Kidney cancer
- NCT number
- NCT07402109
What you commit to
- Study type: Interventional
- Planned participants: 40
- From Apr 2026 to the primary completion date, Jan 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous high-dose radiotherapy in the region of the kidney
Who the study is looking for
- Patients with histologically proven non-metastastic RCC or high suspicion of RCC based on imaging without histological evidence
- No metastatic lesions
- Patients must be 18 years or older
- Ability to understand the requirements of the study and to give written informed consent, as determined by the treating physician.
- Written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Erasmus MC Coordinator of this site? Confirm its status | Rotterdam | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.